Abstract:Abstract Background The body responds to overnutrition by converting stem cells to adipocytes. In vitro and in vivo studies have shown polyphenols and other natural compounds to be anti-adipogenic, presumably due in part to their antioxidant properties. Purpurin is a highly antioxidative anthraquinone and previous studies on anthraquinones have reported numerous biological activities in cells and animals. Anthraquinones have also been used to stimulate osteoblast differentiation, an inversely-related process to that of adipocyte differentiation. We propose that due to its high antioxidative properties, purpurin administration might attenuate adipogenesis in cells and in mice. Methods Our study will test the effect purpurin has on adipogenesis using both in vitro and in vivo models. The in vitro model consists of tracking with various biomarkers, the differentiation of pre-adipocyte to adipocytes in cell culture. The compound will then be tested in mice fed a high-fat diet. Murine 3T3-L1 preadipocyte cells were stimulated to differentiate in the presence or absence of purpurin. The following cellular parameters were measured: intracellular reactive oxygen species (ROS), membrane potential of the mitochondria, ATP production, activation of AMPK (adenosine 5′-monophosphate-activated protein kinase), insulin-induced lipid accumulation, triglyceride accumulation, and expression of PPARγ (peroxisome proliferator activated receptor-γ) and C/EBPα (CCAAT enhancer binding protein α). In vivo, mice were fed high fat diets supplemented with various levels of purpurin. Data collected from the animals included anthropometric data, glucose tolerance test results, and postmortem plasma glucose, lipid levels, and organ examinations. Results The administration of purpurin at 50 and 100 μM in 3T3-L1 cells, and at 40 and 80 mg/kg in mice proved to be a sensitive range: the lower concentrations affected several measured parameters, whereas at the higher doses purpurin consistently mitigated biomarkers associated with adipogenesis, and weight gain in mice. Purpurin appears to be an effective antiadipogenic compound. Conclusion The anthraquinone purpurin has potent in vitro anti-adipogenic effects in cells and in vivo anti-obesity effects in mice consuming a high-fat diet. Differentiation of 3T3-L1 cells was dose-dependently inhibited by purpurin, apparently by AMPK activation. Mice on a high-fat diet experienced a dose-dependent reduction in induced weight gain of up to 55%.

Study on Purpurin As A G Protein-coupled Receptor-35 Agonist

Sensitive and Selective Detection of Puerarin Based on the Hybrid of Reduced Graphene Oxide and Molecularly Imprinted Polymer.

Evaluation of the antiproliferative activity of 106 marine microbial metabolites against human lung cancer cells and potential antiproliferative mechanism of purpuride G

Development and Characterization of Fluorescent Probes for the G Protein-Coupled Receptor 35.

Structure-Activity Relationship Studies of Coumarin-like Diacid Derivatives As Human G Protein-Coupled Receptor-35 (hgpr35) Agonists and a Consequent New Design Principle.

The Neuroprotection of Puerarin Against Cerebral Ischemia is Associated with the Prevention of Apoptosis in Rats.

Discovery of 2H-Chromen-2-one Derivatives As G Protein-Coupled Receptor-35 Agonists

Chemical Genomic Analysis of GPR35 Signaling.

5-Nitro-2-(3-Phenylpropylamino)benzoic Acid Is a GPR35 Agonist

The Pathophysiological Functions and Therapeutic Potential of GPR39: Focus on Agonists and Antagonists

Anti-adipogenic and anti-obesity activities of purpurin in 3T3-L1 preadipocyte cells and in mice fed a high-fat diet

Cell Membrane Chromatography Coupled with UHPLC–ESI–MS/MS Method to Screen Target Components from Peucedanum Praeruptorum Dunn Acting on Α1a Adrenergic Receptor

Research progress of purine competitive antagonists

Identification of Physiologically Active Substances as Novel Ligands for MRGPRD

GPER binding site detection and description: a flavonoid-based docking and molecular dynamics simulations study.

SAR Studies of N-[2-(1H-Tetrazol-5-yl)phenyl]benzamide Derivatives As Potent G Protein-Coupled Receptor-35 Agonists.

In silico design of novel probes for the atypical opioid receptor MRGPRX2

Reevaluating GPR30: A Paradigm Shift from Estrogen Receptor to Unique Hydrophilic Ligand Activation

Expression and Purification of Human Membrane Progestin Receptor α (mPRα)

Purpurin suppresses atopic dermatitis via TNF-α/IFN-γ-induced inflammation in HaCaT cells

GPR30 Activation Contributes to the Puerarin-Mediated Neuroprotection in MPP+-Induced SH-SY5Y Cell Death